Phase 3 study of CNM Au 8 for Amyotrophic lateral sclerosis
Latest Information Update: 28 Jun 2023
At a glance
- Drugs CNM Au8 (Primary)
- Indications Amyotrophic lateral sclerosis
- Focus Therapeutic Use
- 28 Jun 2023 New trial record
- 21 Jun 2023 The Clene Nanomedicine media release, the company announces closing of underwritten public offering of $40 Million and the company is utilizing the capital raised in this offering to accelerate regulatory discussions and submissions with the FDA together with planning and preparation for commencing this trial.